<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03059992</url>
  </required_header>
  <id_info>
    <org_study_id>SCY-078-301</org_study_id>
    <secondary_id>2017-000381-29</secondary_id>
    <nct_id>NCT03059992</nct_id>
  </id_info>
  <brief_title>Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases</brief_title>
  <acronym>FURI</acronym>
  <official_title>Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scynexis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scynexis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy
      and safety of SCY-078 in patients ≥ 18 years of age with a documented fungal disease that has
      been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy
      and safety of SCY-078 in patients ≥ 18 years of age with a documented invasive and/or severe
      fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC)
      antifungal treatment. Patients will be treated with SCY-078 for up to 90 days.

      Subjects must have a proven or probable fungal disease and meet all study criteria to be
      considered for enrollment. Eligible subjects must also have documented evidence of failure
      of, intolerance to, or toxicity related to a currently approved SoC antifungal treatment.

      Subjects will also be considered for enrollment if they have an eligible fungal disease and,
      in the judgement of the investigator, the subject cannot receive approved oral antifungal
      options (e.g. susceptibility of the organism or risk for drug-drug interactions) and a
      continued IV antifungal therapy is not desirable or feasible due to clinical or logistical
      circumstances.

      Following a screening visit, there will be up to 11 treatment visits, a follow-up visit and 2
      follow-up contacts.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open label, non-comparator, single arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Global Response</measure>
    <time_frame>Up to 90 days of study treatment</time_frame>
    <description>The proportion of subjects with a complete or partial Global Response (GR) at the End of Treatment Visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Recurrence of Baseline Fungal Infection</measure>
    <time_frame>up to 42 days after end of study treatment</time_frame>
    <description>The proportion of subjects with a recurrence of the baseline fungal infectoin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of survival</measure>
    <time_frame>Day 42, Day 84</time_frame>
    <description>Proportion of surviving subjects</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Invasive Candidiases</condition>
  <condition>Mucocutaneous Candidiasis</condition>
  <arm_group>
    <arm_group_label>SCY-078</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCY-078</intervention_name>
    <description>Experimental Study Drug</description>
    <arm_group_label>SCY-078</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be ≥ 18 years of age with a documented eligible invasive and/or severe fungal disease
             that is refractory or intolerant to Standard-of-Care treatment

          2. Be able to tolerate medication orally or through a nasogastric (NG) tube or
             percutaneous endoscopic gastrostomy (PEG) tube

          3. Must be able to understand and sign a written informed consent form (ICF), which must
             be obtained prior to treatment and any study-related procedures.

          4. Be able to understand and sign a consent or authorization form which shall permit the
             use, disclosure and transfer of the subject's personal health information. (e.g., in
             the U.S. HIPAA Authorization form).

          5. Be able to understand and follow all study-related procedures including study drug
             administration.

          6. Agree to use a medically acceptable method of contraception while receiving
             protocol-assigned product.

        Exclusion Criteria:

          1. An invasive fungal disease with CNS, cardiac or eye involvement.

          2. A life expectancy &lt; 3 days.

          3. Subjects has a known or estimated creatinine clearance of &lt;20 mL/min by Cockroft
             Gault. Estimated creatinine clearance = [(140-age) x weight in Kg]/[72x serum
             creatinine in mg/dL) [x 0.85 if female]. Subjects undergoing dialysis.

          4. Subject with abnormal liver test parameters: aspartate aminotransferase (AST), alanine
             aminotransferase (ALT) &gt;10 x the upper limit of normal (ULN), and/or total bilirubin &gt;
             5 x ULN. Patients with unconjugated hyperbilirubinemia with diagnosis of Gilbert's
             disease are not excluded.

          5. There is inappropriate fungal infection source control e.g., persistent catheters,
             devices, identified abscess likely to be the source of the fungal infection.

          6. Subject is hemodynamically unstable or and/or requiring vasopressor medication for
             blood pressure support.

          7. Subject requires treatment with the prohibited medications.

          8. Subject with a known hypersensitivity to SCY-078 drug under study.

          9. Subject with &lt; 500 absolute neutrophils per mL at baseline. NOTE: Patients with an
             absolute neutrophil count (ANC) &lt; 500/mm3 who are receiving G-CSF are allowed to
             enroll if the patient is expected to recover from the severe neutropenia (ANC &lt;
             500/mm3) in 3 to 5 days after starting with G-CSF treatment and if the patient is
             expected to meet inclusion/exclusion criteria at the time of reevaluation.

         10. Subject is pregnant or lactating.

         11. Subject has used an investigational drug within 30 days prior to the baseline visit.

         12. Any other condition or laboratory abnormality that, in the judgment of the
             investigator, would put the subject at unacceptable risk for participation in the
             study or may interfere with the assessments included in the study.

         13. Prolonged QTc (Fridericia's correction: QTc = QT/RR0.33) &gt; 480 findings on the
             baseline ECG or other abnormalities deemed clinically significant by the investigator
             that would put the subject at unacceptable risk for participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Angulo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Angulo, MD</last_name>
    <phone>201-884-5471</phone>
    <email>david.angulo@scynexis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristin Bennett</last_name>
    <phone>201-884-5469</phone>
    <email>kristin.bennett@scynexis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alisa Pinhehardt</last_name>
      <phone>205-934-9661</phone>
      <email>apeinhardt@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Pappas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Trigg</last_name>
      <phone>916-734-8033</phone>
      <email>ktconant@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>George Thomposn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Carpentieri</last_name>
      <phone>404-712-7245</phone>
      <email>cynthia.t.smith@emory.edu</email>
    </contact>
    <investigator>
      <last_name>George Lyon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aprile Osborn</last_name>
      <phone>706-721-0309</phone>
      <email>aosborn@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Jose Vazquez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Theusch</last_name>
      <phone>773-702-1665</phone>
      <email>jtheusch@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Mullane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Weiser</last_name>
      <phone>504-210-3403</phone>
      <email>sweise@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Hagensee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Weiser</last_name>
      <phone>504-568-7740</phone>
    </contact>
    <investigator>
      <last_name>Michael Hagensee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casey Dahl</last_name>
      <phone>612-626-3798</phone>
      <email>dahl0465@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Jo-Anne Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Kessels</last_name>
      <phone>314-747-1096</phone>
    </contact>
    <contact_backup>
      <email>lkessels@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrej Spec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Munoz</last_name>
      <phone>631-638-0844</phone>
      <email>sebastian.munoz@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Henry Neumann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Wright</last_name>
      <phone>919-668-5571</phone>
      <email>diane.wright@dm.duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Libyadda Mosley</last_name>
      <phone>336-716-3266</phone>
      <email>limosley@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>John Sanders, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburg Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Lingg</last_name>
      <phone>412-648-6536</phone>
      <email>linggtm@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Minh-Hong Nguyen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri Dixon</last_name>
      <phone>615-343-0266</phone>
      <email>sheri.dixon@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Gowri Satyanarayana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8589</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giselle Huet</last_name>
      <phone>214-648-9464</phone>
      <email>giselle.huet@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Ricardo LaHoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelbie Martin</last_name>
      <phone>713-704-4137</phone>
      <email>shelbie.a.martin@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Luis Ostrosky-Zeichner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meg Bayless</last_name>
      <phone>608-262-8156</phone>
    </contact>
    <investigator>
      <last_name>David Andes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz Department of Internal Medicine, Department of Pulmology, Section for Infectious Disease and Tropical Medicine</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jurgen Prattes</last_name>
      <phone>+43 316 385 30046</phone>
    </contact>
    <investigator>
      <last_name>Robert Krause, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Decristoforo</last_name>
      <phone>0049 6676 8716 72722</phone>
      <email>petra.decristoforo@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Günter Weiss, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Eschertzhuber, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln, Klinik I für Innere Medizin</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Proske</last_name>
      <phone>0221 478-85504</phone>
      <email>susanna.proske@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Oliver Cornely, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Infektiologie</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerlinde Augustiniak</last_name>
      <phone>0049 201 723 6022</phone>
      <email>gerlinde.augustiniak@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Oliver Witzke, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Department of Internal Medicine II</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franziska Ebeling</last_name>
      <phone>0049 69 6301 6140</phone>
      <email>franziska.ebeling@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Stephan, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Georg gGmbH Department for Infectious Disease, Tropical Medicine and Nephrology</name>
      <address>
        <city>Leipzig</city>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Schmidt</last_name>
      <phone>0049 341 909 4472</phone>
      <email>ulrike.schmidt@sanktgeorg.de</email>
    </contact>
    <investigator>
      <last_name>Bernhard Ruf, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität München, Medizinische Klinik und Poliklinik III</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Illenyi</last_name>
      <phone>0049 89 4400 75211</phone>
      <email>marta.illenyi@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Helmut Ostermann, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Candidiasis, Chronic Mucocutaneous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

